CRL
Charles River Laboratories International IncHealth Caresp500Everything we've seen
- !Jun 2, 7:01 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 1, 6:02 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !Jun 1, 7:01 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !May 29, 6:03 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- !May 29, 7:01 AMsignal
Agent 6 — Options Momentum — insufficient_capital
- !May 28, 6:00 PMsignal
Agent 6 — Options Momentum — insufficient_capital
- ?May 28, 9:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up ~4.95% today with no attributable headline, suggesting institutional flow or a catalyst not yet surfaced in news feeds. A move of this magnitude reflects genuine conviction from someone with size. However, several factors temper enthusiasm: (1) 380 minutes remaining is actually a full trading day's worth — today is likely early session, meaning the move has already run and there is significant time for profit-taking and mean reversion; (2) macro context shows T10Y3M at 1.8σ above trend, which is mildly risk-on for equities broadly but CRL (Charles River Laboratories) is a life sciences CRO — not a primary beneficiary of yield curve steepening, and could face headwinds if recession-sensitive sentiment builds; (3) no news to sustain narrative momentum increases fade risk as the day progresses; (4) a ~5% gap/run without a clear catalyst is susceptible to late-session giveback as early buyers trim. On balance, the base momentum case supports slight continuation, but there is no strong accelerant. Probability sits just above the threshold, reflecting ordinary momentum with no strong reason to reverse but no clear fuel for further extension.
- !May 28, 9:25 AMsignalseverity 0.05
Agent 7 — Day Trader — day_trade_skipped
CRL is up ~4.95% today with no attributable headline, suggesting institutional flow or a catalyst not yet surfaced in news feeds. A move of this magnitude reflects genuine conviction from someone with size. However, several factors temper enthusiasm: (1) 380 minutes remaining is actually a full trading day's worth — today is likely early session, meaning the move has already run and there is significant time for profit-taking and mean reversion; (2) macro context shows T10Y3M at 1.8σ above trend, which is mildly risk-on for equities broadly but CRL (Charles River Laboratories) is a life sciences CRO — not a primary beneficiary of yield curve steepening, and could face headwinds if recession-sensitive sentiment builds; (3) no news to sustain narrative momentum increases fade risk as the day progresses; (4) a ~5% gap/run without a clear catalyst is susceptible to late-session giveback as early buyers trim. On balance, the base momentum case supports slight continuation, but there is no strong accelerant. Probability sits just above the threshold, reflecting ordinary momentum with no strong reason to reverse but no clear fuel for further extension.
- ?May 28, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.29 cash available; close=$164.49.
- !May 28, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$164.49.
- ?May 28, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $8.03 cash available; close=$164.49.
- !May 28, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $9.46 cash available; close=$164.49.
- ?May 27, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$164.49.
- ?May 27, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
There are no recent news headlines or SEC filings available to explain the 15.5% drop from CRL's 30-day high, suggesting the move may be driven by macro or sector-rotation forces rather than company-specific deterioration. Charles River Laboratories (CRL) is an established CRO/preclinical services company with a historically solid balance sheet, though the sector has faced headwinds from biotech funding cycles and drug development outsourcing trends. The macro context shows a steepening yield curve (T10Y3M at 1.9σ above trend), which tends to pressure growth-oriented and recession-sensitive sectors, and CRL's revenue is partly tied to biotech client spending cycles that can be sensitive to credit conditions.
- !May 27, 6:01 PMsignalseverity 0.15
Agent 4 — Dip Buyer (Frozen) — dip_skipped
There are no recent news headlines or SEC filings available to explain the 15.5% drop from CRL's 30-day high, suggesting the move may be driven by macro or sector-rotation forces rather than company-specific deterioration. Charles River Laboratories (CRL) is an established CRO/preclinical services company with a historically solid balance sheet, though the sector has faced headwinds from biotech funding cycles and drug development outsourcing trends. The macro context shows a steepening yield curve (T10Y3M at 1.9σ above trend), which tends to pressure growth-oriented and recession-sensitive sectors, and CRL's revenue is partly tied to biotech client spending cycles that can be sensitive to credit conditions.
- !May 27, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Net signal score: +3. Positive signals: (1) unusual call volume with a very low P/C ratio of 0.28 (put z-score of -3.25 is extremely low, confirming call-side dominance — informed buying signal on a dipping stock, +1); (2) sector underperformance (Health Care ranks 7/11 by 30d relative strength, down 8.09pts vs SPY over 30 days — the dip is sector-wide, not idiosyncratic, +1); (3) drop magnitude of 15.5% from 30-day high without any identifiable fundamental cause (no adverse filings, no negative headlines, +1); (4) no earnings within 30 days (+1). Negative signals: (1) 10Y yield at 4.56%, modestly above the ~4.5% threshold for duration-sensitive names (-1 partial, though CRL as a CRO/life sciences services company is more value/defensive than pure growth, so applying -0.5 softly). VIX at 16.59 (35th percentile) is benign — no negative signal. No hard vetoes fired. The absence of any news, insider sells, or fundamental deterioration combined with the strongly bullish options flow makes this a credible mean-reversion setup. Anchoring at 55-60% base rate and adjusting up for the +3 net score yields ~0.61, modestly tempered by the slightly elevated 10Y yield.
- ?May 27, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.46 cash available; close=$164.49.
- !May 27, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
CRL (Charles River Laboratories) is down 15.5% from its 30-day high with no confirmed fundamental catalyst visible — no negative headlines, no adverse SEC filings, and no insider selling. The drop appears to be sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY by ~8pts over 30 days, ranking 7th of 11 sectors. Critically, options flow on 2026-05-27 is strongly bullish with unusual call volume (z=0.70) and dramatically suppressed put volume (z=-3.25), yielding a P/C ratio of only 0.28 — this asymmetric skew toward calls on a dipping stock is a meaningful confirmation signal of informed accumulation. VIX at the 35th percentile reflects a low-fear environment supportive of mean reversion trades.
- ?May 27, 1:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 3.64% today with no attributable headline, suggesting institutional flow or a delayed reaction to a catalyst (earnings revision, analyst action, or sector rotation). The move is meaningful in size and likely reflects real conviction. However, several factors temper enthusiasm: (1) No news to anchor the narrative or attract fresh buyers into the close. (2) 150 minutes remaining is ample time but also means the move has already run most of the session without accelerating into a clear trend — risk of mid-session profit-taking increases. (3) Macro context shows T10Y3M at +1.9σ above trend, signaling a steepening yield curve that is mildly supportive of risk assets but does not directly benefit CRL (a CRO/life sciences services company), which is not in the directly reactive sectors (Banks, Recession-sensitive). (4) Absence of a reversal pattern or fade signal argues against going contrarian. On balance, the default momentum edge plus no fade signal pushes probability just above 0.5, but the lack of news, no fresh catalyst, and already-mature intraday move keep conviction modest.
- !May 27, 1:16 PMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
CRL is up 3.64% today with no attributable headline, suggesting institutional flow or a delayed reaction to a catalyst (earnings revision, analyst action, or sector rotation). The move is meaningful in size and likely reflects real conviction. However, several factors temper enthusiasm: (1) No news to anchor the narrative or attract fresh buyers into the close. (2) 150 minutes remaining is ample time but also means the move has already run most of the session without accelerating into a clear trend — risk of mid-session profit-taking increases. (3) Macro context shows T10Y3M at +1.9σ above trend, signaling a steepening yield curve that is mildly supportive of risk assets but does not directly benefit CRL (a CRO/life sciences services company), which is not in the directly reactive sectors (Banks, Recession-sensitive). (4) Absence of a reversal pattern or fade signal argues against going contrarian. On balance, the default momentum edge plus no fade signal pushes probability just above 0.5, but the lack of news, no fresh catalyst, and already-mature intraday move keep conviction modest.
- ?May 27, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$156.73.
- !May 27, 7:01 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $22.31 cash available; close=$156.77.
- ?May 27, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $21.36 cash available; close=$156.73.
- !May 27, 7:01 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $2.08 cash available; close=$156.77.
- ?May 26, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 26, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $22.31 cash available; close=$156.77.
- !May 26, 6:01 PMsignalseverity 0.19
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- !May 26, 6:01 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$160.30.
- ?May 26, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $2.08 cash available; close=$156.77.
- !May 26, 6:01 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
Wanted to buy but only $0.00 cash available; close=$160.30.
- ?May 26, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$160.30.
- !May 26, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Step 1 — No hard vetoes fire: no imminent earnings, no recent filings revealing fundamental deterioration, and the sector is not in freefall this week (+2.43pts vs SPY over 5 days). Step 2 — Positive signals: (1) drop ≥15% from 30-day high without any disclosed fundamental cause (+1); (2) unusual call volume relative to recent norms (z=+1.53) on a dipping stock with a notably low P/C ratio of 0.28, suggesting informed bullish positioning (+1); (3) sector underperforming on a 30-day basis (−7.99pts vs SPY), consistent with a sector-wide rather than idiosyncratic dip (+1); (4) no earnings in visible window (+1). Negative signals: (1) 10Y yield at 4.57% is above the ~4.5% threshold, a mild structural headwind for a healthcare/CRO-type name (−1). Net signal score: +3. With a net score of +3 and no hard vetoes, the base rate (~57%) is adjusted upward modestly. The strong call flow skew (P/C 0.28) and sector-wide context are the most conviction-building signals, but the absence of any fundamental filings or insider activity limits confidence, anchoring rebound_probability at 0.59.
- ?May 26, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$160.30.
- !May 26, 7:02 AMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
CRL (Charles River Laboratories) is down 17.6% from its 30-day high with no identifiable fundamental catalyst — no negative news headlines, no SEC filings signaling deterioration, and no insider selling. The options flow is notably bullish: call volume is elevated at a z-score of +1.53 while put volume is suppressed (z=-1.32), yielding a very low P/C ratio of 0.28, suggesting informed participants are positioning for upside. The Health Care sector has underperformed SPY by ~8pts over 30 days, indicating the drop is more sector-driven than idiosyncratic to CRL, which supports a mean-reversion thesis. VIX is at a benign 40th percentile, macro conditions are not in crisis, and no imminent earnings overhang is present.
- ?May 22, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- !May 22, 6:01 PMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 22, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- !May 22, 6:01 PMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 22, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- !May 22, 6:01 PMsignalseverity 0.18
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 22, 9:26 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 1.81% today, a modest but real move suggesting some institutional flow. There are no headlines to explain the move, which is common and not disqualifying. With 380 minutes remaining (essentially a full trading day still ahead given this is early/mid session), there is ample time for continuation. However, the macro context is a mild headwind: the T10Y3M spread is 2.2σ above trend, signaling elevated yield curve steepness which can pressure recession-sensitive names — CRL (Charles River Laboratories) is a contract research organization with some cyclical sensitivity. The move at 1.81% is below the 2-5% 'strong conviction' threshold, so momentum signal is moderate rather than strong. No clear reversal pattern is indicated. On balance, the setup warrants a lean-up with modest conviction — the time remaining and lack of contrary news support taking the trade, but macro headwinds and sub-threshold move magnitude keep the probability near the floor of the action zone.
- !May 22, 9:26 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 1.81% today, a modest but real move suggesting some institutional flow. There are no headlines to explain the move, which is common and not disqualifying. With 380 minutes remaining (essentially a full trading day still ahead given this is early/mid session), there is ample time for continuation. However, the macro context is a mild headwind: the T10Y3M spread is 2.2σ above trend, signaling elevated yield curve steepness which can pressure recession-sensitive names — CRL (Charles River Laboratories) is a contract research organization with some cyclical sensitivity. The move at 1.81% is below the 2-5% 'strong conviction' threshold, so momentum signal is moderate rather than strong. No clear reversal pattern is indicated. On balance, the setup warrants a lean-up with modest conviction — the time remaining and lack of contrary news support taking the trade, but macro headwinds and sub-threshold move magnitude keep the probability near the floor of the action zone.
- ?May 22, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- !May 22, 7:01 AMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 22, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- !May 22, 7:01 AMsignalseverity 0.18
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 21, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- !May 21, 6:01 PMsignalseverity 0.18
Agent 5 — Dip Buyer (Evolving) — dip_skipped
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 21, 6:00 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- !May 21, 6:00 PMsignalseverity 0.18
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 21, 6:00 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- !May 21, 6:00 PMsignalseverity 0.18
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 21, 2:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.36% with no attributable headline, suggesting the move is driven by either sector rotation or quiet institutional accumulation rather than a news catalyst. With 90 minutes remaining there is reasonable time for continuation, but the elevated 10Y inflation breakeven (2.44, ~1.7σ above trend) is a mild headwind for longer-duration sensitive names and adds some macro friction. No reversal signals are visible from the data provided, and the move is meaningful enough to reflect real flow. Without a clear catalyst or strong sector tailwind, this is a borderline ordinary momentum read — slight edge to continuation given the system's asymmetric risk structure, but conviction is modest.
- !May 21, 2:15 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
CRL is up 2.36% with no attributable headline, suggesting the move is driven by either sector rotation or quiet institutional accumulation rather than a news catalyst. With 90 minutes remaining there is reasonable time for continuation, but the elevated 10Y inflation breakeven (2.44, ~1.7σ above trend) is a mild headwind for longer-duration sensitive names and adds some macro friction. No reversal signals are visible from the data provided, and the move is meaningful enough to reflect real flow. Without a clear catalyst or strong sector tailwind, this is a borderline ordinary momentum read — slight edge to continuation given the system's asymmetric risk structure, but conviction is modest.
- ?May 21, 11:47 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 21, 11:47 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 21, 11:46 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 21, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 21, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 20, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 20, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 20, 6:01 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 20, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 20, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ▣May 19, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $10.97 (+$91.83)
Stop: premium $10.97 ≤ trailing floor $11.18 (peak $14.90 × 0.75)
- ?May 19, 6:02 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 19, 6:02 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 19, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 19, 2:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 2.11% today with no attributable headline, suggesting the move is likely flow/positioning-driven. With 75 minutes remaining there is still meaningful time for continuation, but 75 minutes is not ample — the window is narrowing. The macro context (elevated 10Y inflation expectations at 2.4σ above trend) creates a mild headwind for longer-duration sensitive equities, though CRL as a contract research organization is only modestly rate-sensitive. No reversal signal is evident from the data provided, and the 2.11% move reflects real conviction from size participants. Absence of news does not disqualify continuation. The setup is marginally favorable but lacks strong catalysts or sector tailwinds, placing this squarely in the ordinary momentum bucket with no strong reason to fade. Probability set just above the 0.5 threshold.
- ?May 19, 1:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 1.52% today with no headline catalyst identified, suggesting the move may be flow-driven or sector-rotation related rather than a fundamental shock. The macro context shows 10-year inflation expectations elevated at 2.4σ above trend, which creates a modest headwind for long-duration sensitive names — CRL as a contract research organization carries some duration sensitivity given its growth/services profile. With 164 minutes remaining, there is meaningful time for continuation, but the move magnitude (1.52%) is below the threshold of a strong conviction signal. No reversal pattern is evident from the data provided, and absence of news does not disqualify the setup. On balance, momentum is mildly constructive, but the elevated inflation expectations macro backdrop introduces a slight fade risk for this type of name. Probability sits just above the action threshold — ordinary momentum with no strong reversal signal, but no strong tailwind either.
- ?May 19, 11:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
CRL is up 1.80% today with no attributable headline catalyst, suggesting organic flow rather than a news-driven spike that might fade quickly. The move is modest (below the 2-5% high-conviction threshold), which limits strong momentum continuation signals. Macro context shows elevated 10-year inflation expectations (T10YIE at 2.4σ above trend), which is a mild headwind for long-duration sensitive equities, though CRL as a contract research organization has moderate duration sensitivity. With 275 minutes remaining there is ample time for continuation, but the lack of news and relatively small move size keep conviction moderate. No reversal signals are evident. Net assessment: slight lean toward continuation given time remaining and no fade catalyst, but confidence is low — sitting just above the 0.5 threshold.
- ?May 19, 9:28 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly references CRL shares "plummeting," suggesting a company-specific catalyst drove the ~23% drawdown rather than pure macro rotation. The absence of any recent SEC filings (no 8-K explaining a restatement or minor event, no updated guidance) combined with a significant single-name drop is a red flag — large moves without official disclosure often follow a surprise earnings miss, guidance cut, or structural business concern that hasn't been fully digested. The elevated 10-year inflation breakeven (2.48, 2.4σ above trend) adds a macro headwind for a capital-intensive CRO/lab services business sensitive to rate and cost pressures.
- ?May 19, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL is down 22.9% from its 30-day high, a significant drop that qualifies as a mean-reversion candidate (+1), and no imminent earnings are visible to create binary risk (+1). Options flow is notably bullish with a P/C ratio of 0.36 on meaningful call volume relative to puts (+1). However, the sector (Health Care/XLV) is ranked 10 of 11 by 30-day relative strength and is underperforming SPY by -12.48pts over 30 days — this is sector-wide weakness, which is a mild positive (dip not purely idiosyncratic, +1), but also signals genuine sector headwinds. Macro is a headwind: 10Y at 4.59% above the ~4.5% threshold (-1), and inflation expectations (T10YIE at 2.4σ above trend) create pressure on long-duration/growth-sensitive names. No insider buying and no recent SEC filings leave the fundamental picture unclear, limiting conviction. Net signal score: approximately +3 positive, -1 negative = +2, but the lack of any insider confirmation and the sharp sector underperformance (near freefall territory) temper conviction, pulling rebound probability just below the buy threshold.
- ?May 19, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 18, 12:20 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The headline explicitly flags that CRL shares "plummeted," suggesting a company-specific event rather than pure macro noise — though the exact catalyst is not detailed in the available evidence. The absence of recent SEC filings (no 10-K/10-Q/8-K) means we cannot verify the financial health or rule out a guidance cut, earnings miss, or operational deterioration. Given the severity of the 20.6% drop and the ambiguous but negative news signal, caution is warranted and financial soundness cannot be confirmed.
- ?May 18, 9:25 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL is down 22.5% from its 30-day high and the news headlines reference shares "plummeting," suggesting a sharp negative catalyst (likely a guidance cut or earnings miss) rather than a purely macro-driven move. The Health Care sector is already the second-worst performer on 30-day relative strength (rank 10 of 11, -13.87pts vs SPY), indicating sector headwinds are compounding an apparent company-specific negative event. With no insider buying, no confirmatory options flow, a strongly negative sector flow proxy (-13.8M), and a broad market risk-off day (SPY -1.20%, IWM -2.41%), there are no meaningful confirmation signals to support a near-term rebound. Macro conditions are neutral (VIX at 50th percentile, 10Y at 4.47%) but provide no tailwind.
- ?May 18, 9:00 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — analyze: fail
Analyze call failed: No JSON object in analysis response: I'll work through the analytical framework systematically. **STEP 1 — HARD VETO CHECK:** - Earnings: No upcoming earnings in visible window → No veto - Fundamental deterioration: No recent 10-Q/10-K/
- ?May 18, 8:54 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
With no recent news headlines or SEC filings available to explain the 22.5% drawdown from the 30-day high, the drop cannot be attributed to confirmed fundamental deterioration such as guidance cuts, fraud, or structural business impairment. However, the absence of evidence is not evidence of absence — CRL (Charles River Laboratories) operates in contract research/life sciences services, a sector under prolonged pressure from biotech funding tightness and customer budget cuts that predate this window. The elevated 5-year inflation breakeven at 2.5σ above trend introduces additional macro headwinds via higher discount rates and potential cost pressures, offering no meaningful tailwind for a rebound.
- ❖May 17, 5:24 AMnewsvia finnhub
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales.
- ✓May 16, 6:35 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
CRL (Charles River Laboratories) has dropped 22.5% from its 30-day high to $150.85, a meaningful dip with no confirmed fundamental impairment visible in the available evidence window. No negative SEC filings, no earnings announcement imminent, no insider selling, and no unusual put flow have been detected — meaning the drop lacks a confirmed company-specific negative catalyst in this data set. The broader macro context is mixed but not severely hostile: VIX at 17.26 is at the 50th percentile (moderate), the 2s10s spread is positive at +0.47pp (not inverted), and the 10Y at 4.47% is slightly below the typical structural headwind threshold of 4.5%. Today's broad market weakness (SPY -1.20%, IWM -2.41%) suggests macro/risk-off pressure is contributing to the dip rather than company-specific deterioration, which is a mild constructive signal for mean reversion. The healthcare sector dip context is unavailable, so we cannot determine idiosyncratic vs. sector-driven causation — this introduces uncertainty rather than a clear negative signal. The 5Y inflation breakeven printing 2.7 (2.5σ above trend) is more relevant to commodities and TIPS than to a CRO/healthcare services name like CRL. The absence of insider cluster buys, options call flow confirmation, or visible near-term positive catalysts keeps the probability from reaching the high-conviction range. On valuation, the drop from ~$195 to ~$151 represents a historically significant discount for a company with CRL's track record in preclinical research services, though without current P/E or EV/EBITDA data this cannot be confirmed precisely. Balancing a material unexplained price drop with no confirmed negative catalyst, neutral macro, and no confirmation signals, this qualifies as a mixed-evidence situation warranting a modest buy in the paper-trading context.
- ?May 16, 10:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
CRL (Charles River Laboratories) is down 22.5% from its 30-day high, trading at $150.85 vs. a $194.57 peak. The evidence base is almost entirely empty: no recent news headlines, no SEC filings, no insider activity, no options flow, and no visible earnings catalyst. Without knowing the cause of the 22.5% decline, there is no way to assess whether it reflects temporary sentiment, a sector rotation, or deteriorating fundamentals. The absence of any cluster insider buying removes what would otherwise be a strong mean-reversion signal. The macro environment adds further headwinds: the 5Y inflation breakeven printing 2.7% (2.5σ above trend) suggests sticky inflation concerns, the 10Y yield at 4.47% is near the structural headwind threshold, and today's broad market is risk-off (SPY -1.20%, IWM -2.41%, QQQ -1.51%), with small caps and growth notably weak. VIX at the 50th percentile is not alarming but does not provide a contrarian signal either. The health care sector has no flow data provided, making it impossible to determine whether CRL's drop is idiosyncratic or sector-driven. Given the complete information vacuum surrounding the catalyst, the absence of any bullish confirming signals (insider buys, unusual call flow, sector outperformance), and a risk-off macro day, the conservative posture is to pass on this trade.
- ?May 16, 9:19 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
CRL (Charles River Laboratories) has dropped 22.5% from its 30-day high to $150.85, a significant drawdown. However, the evidence base is almost entirely empty: no recent news headlines, no SEC filings, no insider activity, no options flow, and no visible earnings catalyst. Without knowing the fundamental driver of this decline, it is impossible to assess whether the drop represents a mispricing or a justified re-rating. The absence of any insider buying — which would typically emerge quickly after a stock drops this sharply if insiders believed it was oversold — is a meaningful negative signal given the 30-day window available. Macro context is mixed-to-negative: the 10Y at 4.47% is near the headwind threshold for growth-sensitive Healthcare names, VIX at the 50th percentile is neutral but today's broad market selloff (SPY -1.20%, IWM -2.41%) suggests risk-off conditions. The elevated 5Y inflation breakeven (T5YIE at 2.7, 2.5σ above trend) adds macro uncertainty. The 2s10s spread is mildly positive (+0.47pp), providing no recessionary signal, but this is a minor positive offset. With zero confirmatory signals (no insider cluster buy, no unusual call flow, no sector tailwind data, no fundamental clarity on the selloff cause), the risk-reward does not meet the threshold for a 90-day swing trade entry.
- ❖May 16, 2:34 AMnewsvia finnhub
What Moved Markets This Week
U.S. stocks ended the week mostly unchanged amid persistent inflation pressures and surging Treasury yields. Read more about this week's major events on Wall Street.
- ▢May 13, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $10.05